No results for ‘’
Sanofi India Ltd
NSE: SANOFI BSE: 500674
â‚ą3346.90
(0.27%)
Mon, 13 Jul 2026, 01:36 am
Market Cap (in Cr)7782.41
PE Ratio24.88
Dividend3.64
Health Technology
Pharmaceuticals: Major
24.5KSanofi India Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are covered by earnings (1.7x coverage).
- Sanofi India's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Sanofi India's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Sanofi India is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Sanofi India is profitable, therefore cash runway is not a concern.
- Sanofi India is profitable, therefore cash runway is not a concern.
- Sanofi India has no debt, it does not need to be covered by operating cash flow.
- Sanofi India has no debt, it does not need to be covered by short term assets.
- Sanofi India's cash and other short term assets cover its long term commitments.
- Sanofi India has not taken on any debt in the past 5 years.
- Sanofi India has no debt, therefore coverage of interest payments is not a concern.
- Sanofi India has no debt.
- High level of physical assets or inventory.
management
- The tenure for the Sanofi India board of directors is about average.
- Rajaram's remuneration is about average for companies of similar size in India.
- Rajaram's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Sanofi India management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Sanofi India is not covered by any analysts.
past
- Sanofi India's year on year earnings growth rate has been positive over the past 5 years.
- Sanofi India used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Sanofi India has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Sanofi India's 1-year earnings growth is less than its 5-year average (4% vs 14%)
- Sanofi India has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Sanofi India's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (4% vs 22.7%).
value
- SANOFI outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- SANOFI outperformed the Market in India which returned -14.5% over the past year.
- Sanofi India's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Sanofi India's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Sanofi India is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Sanofi India is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Sanofi India is overvalued based on earnings compared to the India market.
- NSEI:SANOFI is up 2.1% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:SANOFI is up 2.1% underperforming the market in India which returned 8% over the past month.